137 related articles for article (PubMed ID: 30668215)
1. Where do we currently stand with T-cell prolymphocytic leukemia?
Khot A
Leuk Lymphoma; 2019 Mar; 60(3):563-565. PubMed ID: 30668215
[No Abstract] [Full Text] [Related]
2. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
Fox CP; Ahearne MJ; Pettengell R; Dearden C; El-Sharkawi D; Kassam S; Cook L; Cwynarski K; Illidge T; Collins G
Br J Haematol; 2022 Feb; 196(3):507-522. PubMed ID: 34811725
[No Abstract] [Full Text] [Related]
3. Survival trends in T cell prolymphocytic leukemia: A SEER database analysis.
Chandran R; Gardiner SK; Fenske TS; Spurgeon ES
Leuk Lymphoma; 2016; 57(4):942-4. PubMed ID: 26292711
[No Abstract] [Full Text] [Related]
4. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
Sun S; Fang W
Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
[TBL] [Abstract][Full Text] [Related]
5. Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Drozd-Sokolowska J; Gras L; Koster L; Martino R; Salas MQ; Salmenniemi U; Zudaire T; Yañez L; Bellido M; Collin M; Kaufmann M; Kozlowski P; Poiré X; Ferra C; Sampol A; Wilson KMO; Cairoli A; Gedde-Dahl T; Deconinck E; Mirabile M; Suarez F; Raj K; Van Gelder M; Yakoub-Agha I; Tournilhac O; McLornan DP
Haematologica; 2024 May; 109(5):1608-1613. PubMed ID: 38205539
[No Abstract] [Full Text] [Related]
6. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB; Herling M; Bellido M; Jacobsen ED; Davids MS; Kadia TM; Shustov A; Tournilhac O; Bachy E; Zaja F; Porkka K; Hoermann G; Simonitsch-Klupp I; Haferlach C; Kubicek S; Mayerhoefer ME; Hopfinger G; Jaeger U; Dearden C
Blood; 2019 Oct; 134(14):1132-1143. PubMed ID: 31292114
[TBL] [Abstract][Full Text] [Related]
7. T-cell prolymphocytic leukemia presenting as ascites.
Hermans SJF; Sandberg Y
Blood; 2019 Jul; 134(4):411. PubMed ID: 31345928
[No Abstract] [Full Text] [Related]
8. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
9. Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis.
Krassas N; de la Mata Perez G; Jones N
Ocul Immunol Inflamm; 2018; 26(3):376-378. PubMed ID: 27736276
[No Abstract] [Full Text] [Related]
10. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
11. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and survival outcomes of patients with T cell prolymphocytic leukemia in the United States: 2011-2020 analysis of the SEER database.
Wasifuddin M; Ilerhunmwuwa NP; Becerra H; Wang JC
Leuk Lymphoma; 2023 Dec; 64(12):2051-2053. PubMed ID: 37531079
[No Abstract] [Full Text] [Related]
13. T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
[TBL] [Abstract][Full Text] [Related]
14. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia.
Yong HX; Linn YC; Ong KH; Tan D
Leuk Res; 2012 Aug; 36(8):e163-5. PubMed ID: 22613190
[No Abstract] [Full Text] [Related]
16. Extreme hyperlymphocytosis.
Berz D; Freeman NJ
J Clin Oncol; 2008 Feb; 26(4):674-5. PubMed ID: 18235128
[No Abstract] [Full Text] [Related]
17. T-cell Prolymphocytic Leukemia.
Sud A; Dearden C
Hematol Oncol Clin North Am; 2017 Apr; 31(2):273-283. PubMed ID: 28340878
[TBL] [Abstract][Full Text] [Related]
18. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
19. [Chronic T-cell lymphatic leukemia].
Rossetti A; Bonati PL; Zannoni M; Sansoni P
G Clin Med; 1990 Oct; 71(10):593-9, 602-6. PubMed ID: 2289655
[No Abstract] [Full Text] [Related]
20. Recurrent infection in a patient with chronic neutropenia.
Litam PP; Loughran TP
Hosp Pract (Off Ed); 1995 Feb; 30(2):117-8. PubMed ID: 7852460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
